Apogee Therapeutics (APGE) Shares Outstanding (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Shares Outstanding data on file, last reported at $75.3 million in Q1 2026.

• Quarterly Shares Outstanding rose 29.19% year-over-year to $75.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.3 million (up 29.19% YoY) and the FY2025 annual result came in at $69.0 million, up 18.9% from the prior year.
• Shares Outstanding climbed to $75.3 million in Q1 2026 per APGE's latest filing, from $69.0 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $2.5 billion in Q3 2022 and bottomed at $1.2 million in Q2 2022.
• The 5-year median for Shares Outstanding is $56.8 million (2024), against an average of $197.4 million.
• Peak annual rise in Shares Outstanding reached 2874.54% in 2023, while the deepest fall reached 98.08% in 2023.
• Tracing APGE's Shares Outstanding over 5 years: stood at $1.6 million in 2022, then jumped by 2874.54% to $48.3 million in 2023, then climbed by 20.12% to $58.1 million in 2024, then gained by 18.9% to $69.0 million in 2025, then gained by 9.1% to $75.3 million in 2026.
• Per Business Quant, the three latest APGE Shares Outstanding figures stand at $75.3 million (Q1 2026), $69.0 million (Q4 2025), and $59.3 million (Q3 2025).

Peer Comparison